CYTEK BIOSCIENCES, INC. Selling and Marketing Expense
CYTEK BIOSCIENCES, INC. (CTKB) reported Selling and Marketing Expense of $13.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. selling and marketing expense for the quarter ending 2026-06-30 was $13.17M, a 8.57% increase year-over-year.
- CYTEK BIOSCIENCES, INC. selling and marketing expense for the quarter ending 2026-03-31 was $11.65M, a 6.90% decline year-over-year.
- CYTEK BIOSCIENCES, INC. selling and marketing expense for the quarter ending 2025-12-31 was $13.13M, a 10.59% increase year-over-year.
- CYTEK BIOSCIENCES, INC. selling and marketing expense for the quarter ending 2025-09-30 was $11.67M, a 6.14% decline year-over-year.
- CYTEK BIOSCIENCES, INC. selling and marketing expense for fiscal 2025 was $49.44M, a 0.66% increase from fiscal 2024.
- CYTEK BIOSCIENCES, INC. selling and marketing expense for fiscal 2024 was $49.11M, a 0.07% decline from fiscal 2023.
- CYTEK BIOSCIENCES, INC. selling and marketing expense for fiscal 2023 was $49.15M, a 47.90% increase from fiscal 2022.
- CYTEK BIOSCIENCES, INC. selling and marketing expense for fiscal 2022 was $33.23M, a 34.48% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.17M 10-Q · filed 2026-08-05 | $24.82M 10-Q · filed 2026-08-05 | $37.95M derived: sum of 3 quarters · filed 2026-08-05 | $49.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $11.65M 10-Q · filed 2026-05-07 | $24.78M derived: sum of 2 quarters · filed 2026-05-07 | $36.44M derived: sum of 3 quarters · filed 2026-05-07 | $48.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $13.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.80M derived: sum of 2 quarters · filed 2026-02-26 | $36.93M derived: sum of 3 quarters · filed 2026-08-05 | $49.44M 10-K · filed 2026-02-26 |
| 2025-09-30 | $11.67M 10-Q · filed 2025-11-05 | $23.80M derived: sum of 2 quarters · filed 2026-08-05 | $36.31M 10-Q · filed 2025-11-05 | $48.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $12.13M 10-Q · filed 2026-08-05 | $24.64M 10-Q · filed 2026-08-05 | $36.52M derived: sum of 3 quarters · filed 2026-08-05 | $48.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $12.51M 10-Q · filed 2026-05-07 | $24.38M derived: sum of 2 quarters · filed 2026-05-07 | $36.81M derived: sum of 3 quarters · filed 2026-05-07 | $49.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $11.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.30M derived: sum of 2 quarters · filed 2026-02-26 | $36.57M derived: sum of 3 quarters · filed 2026-02-26 | $49.11M 10-K · filed 2026-02-26 |
| 2024-09-30 | $12.43M 10-Q · filed 2025-11-05 | $24.70M derived: sum of 2 quarters · filed 2025-11-05 | $37.24M 10-Q · filed 2025-11-05 | $48.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $12.27M 10-Q · filed 2025-08-06 | $24.81M 10-Q · filed 2025-08-06 | $36.37M derived: sum of 3 quarters · filed 2026-02-26 | $48.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $12.54M 10-Q · filed 2025-05-08 | $24.10M derived: sum of 2 quarters · filed 2026-02-26 | $36.18M derived: sum of 3 quarters · filed 2026-02-26 | $50.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $11.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.64M derived: sum of 2 quarters · filed 2026-02-26 | $38.00M derived: sum of 3 quarters · filed 2026-02-26 | $49.15M 10-K · filed 2026-02-26 |
| 2023-09-30 | $12.08M 10-Q · filed 2024-11-07 | $26.44M derived: sum of 2 quarters · filed 2024-11-07 | $37.59M 10-Q · filed 2024-11-07 | $46.62M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $14.37M 10-Q · filed 2024-08-06 | $25.51M 10-Q · filed 2024-08-06 | $34.54M derived: sum of 3 quarters · filed 2025-02-28 | $43.35M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $11.14M 10-Q · filed 2024-05-08 | $20.17M derived: sum of 2 quarters · filed 2025-02-28 | $28.98M derived: sum of 3 quarters · filed 2025-02-28 | $37.41M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $9.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $17.84M derived: sum of 2 quarters · filed 2025-02-28 | $26.27M derived: sum of 3 quarters · filed 2025-02-28 | $33.23M 10-K · filed 2025-02-28 |
| 2022-09-30 | $8.81M 10-Q · filed 2023-11-14 | $17.24M derived: sum of 2 quarters · filed 2023-11-14 | $24.20M 10-Q · filed 2023-11-14 | $32.51M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $8.43M 10-Q · filed 2023-08-08 | $15.39M 10-Q · filed 2023-08-08 | $23.70M derived: sum of 3 quarters · filed 2024-03-13 | $30.25M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $6.96M 10-Q · filed 2023-05-09 | $15.26M derived: sum of 2 quarters · filed 2024-03-13 | $21.82M derived: sum of 3 quarters · filed 2024-03-13 | $27.39M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $14.86M derived: sum of 2 quarters · filed 2024-03-13 | $20.43M derived: sum of 3 quarters · filed 2024-03-13 | $24.71M 10-K · filed 2024-03-13 |
| 2021-09-30 | $6.55M 10-Q · filed 2022-11-09 | $12.13M derived: sum of 2 quarters · filed 2022-11-09 | $16.41M 10-Q · filed 2022-11-09 | $20.97M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $5.58M 10-Q · filed 2022-08-10 | $9.85M 10-Q · filed 2022-08-10 | $14.41M derived: sum of 3 quarters · filed 2023-03-01 | $18.25M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $4.28M 10-Q · filed 2022-05-12 | $8.84M derived: sum of 2 quarters · filed 2023-03-01 | $12.68M derived: sum of 3 quarters · filed 2023-03-01 | $15.73M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $4.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $8.40M derived: sum of 2 quarters · filed 2023-03-01 | $11.46M derived: sum of 3 quarters · filed 2023-03-01 | $14.99M 10-K · filed 2023-03-01 |
| 2020-09-30 | $3.84M 10-Q · filed 2021-11-12 | $6.90M derived: sum of 2 quarters · filed 2021-11-12 | $10.43M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $3.06M 10-Q · filed 2021-09-03 | $6.59M 10-Q · filed 2021-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |